Search
Now showing items 1-10 of 17
Design challenges facing clinical trials of the effectiveness of new HIV prevention technologies.
(Lippincott Williams & Wilkins., 2012)
Recent successes of antiretroviral pre-exposure prophylaxis (PrEP) in preventing HIV infection
have raised questions whether further placebo controlled trials of new HIV-prevention
technologies are ethically justifiable. ...
Adherence in the treatment of patients with extensively drug-resistant tuberculosis and HIV in South Africa: a prospective cohort study.
(Lippincott Williams & Wilkins., 2014)
Abstract available in pdf.
Preferential adherence to antiretroviral therapy over tuberculosis treatment: a qualitative study of drug-resistant TB/HIV co-infected patients in South Africa.
(Taylor & Francis., 2014)
Abstract available in pdf.
Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial.
(Succop, S.M., MacQueen, K.M., van Loggerenberg, F., Majola, N., Abdool Karim, Q. and Abdool Karim, S.S. 2014. Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial. AIDS care 26(12), 1521-1525., 2014)
Abstract available in pdf.
Using mHealth for HIV/TB treatment support in Lesotho : enhancing patient–provider communication in the START study.
(Wolters Kluwer Health., 2017)
Abstract available in pdf.
Factors affecting first-month adherence to antiretroviral therapy among HIV-positive adults in South Africa.
(Taylor & Francis co-published with NISC., 2010)
This study explores the influence of baseline factors on first-month adherence to highly active antiretroviral therapy (HAART) among adults. The study design involved a review of routinely collected patient information in ...
Recurrent tuberculosis among HIV-coinfected patients: a case series from KwaZulu-Natal.
(Dove Medical Press., 2018)
Abstract available in pdf.
Adherence in the CAPRISA 004 tenofovir gel microbicide trial.
(Springer., 2014)
High adherence is key to microbicide effectiveness. Here we provide a description of adherence
interventions and the adherence rates achieved in the CAPRISA 004 Tenofovir Gel Trial.
Adherence support for the before-and-after ...
Assessing adherence in the CAPRISA 004 tenofovir gel HIV prevention trial: results of a nested case–control study.
(Springer., 2014)
Abstract available in pdf.
Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial.
(Springer., 2014)
Abstract available in pdf.